title: Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
abstract: Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
authors.affiliation: Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.com
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Korpanty
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Smyth
authors.forename: Laura A
authors.initials: LA
authors.lastname: Sullivan
authors.forename: Rolf A
authors.initials: RA
authors.lastname: Brekken
authors.forename: Desmond N
authors.initials: DN
authors.lastname: Carney
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000628:therapy; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009389:Neovascularization, Pathologic; D010880:Piperidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D010880:Piperidines; D011799:Quinazolines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; C452423:vandetanib
references.citation: Clin Adv Hematol Oncol. 2004 Jan;2(1):37-45
references.pmid: 16163158
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1183-92
references.pmid: 16428272
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references.pmid: 17442997
references.citation: J Clin Oncol. 2008 Jan 1;26(1):60-5
references.pmid: 18165641
references.citation: Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L209-21
references.pmid: 16403941
references.citation: Curr Opin Mol Ther. 2005 Oct;7(5):493-501
references.pmid: 16248285
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Endocr Rev. 2004 Aug;25(4):581-611
references.pmid: 15294883
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: N Engl J Med. 2006 Mar 2;354(9):980-2; discussion 980-2
references.pmid: 16514715
references.citation: Cancer Res. 2001 Feb 15;61(4):1309-13
references.pmid: 11245426
references.citation: J Clin Oncol. 2008 Aug 20;26(24):4037-8
references.pmid: 18711196
references.citation: Histol Histopathol. 2004 Jan;19(1):37-42
references.pmid: 14702169
references.citation: J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12
references.pmid: 18520291
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609-14
references.pmid: 9520413
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Am J Kidney Dis. 2007 Feb;49(2):186-93
references.pmid: 17261421
references.citation: Oncologist. 2006 Nov-Dec;11(10):1070-1
references.pmid: 17110625
references.citation: Oncologist. 2004;9 Suppl 1:19-26
references.pmid: 15178812
references.citation: J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9
references.pmid: 18520300
references.citation: Cancer Res. 2005 Jun 1;65(11):4739-46
references.pmid: 15930292
references.citation: J Biol Chem. 1995 Jan 20;270(3):1230-7
references.pmid: 7836384
references.citation: Thorax. 2003 Oct;58(10):892-900
references.pmid: 14514947
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: J Clin Oncol. 2007 Sep 20;25(27):4270-7
references.pmid: 17878479
references.citation: N Engl J Med. 2002 Jan 10;346(2):126-8
references.pmid: 11784881
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2184-91
references.pmid: 15169807
references.citation: Science. 1983 Feb 25;219(4587):983-5
references.pmid: 6823562
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4743-50
references.pmid: 17909199
references.citation: Oncologist. 2007 Oct;12(10):1183-93
references.pmid: 17962612
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2544-55
references.pmid: 15753462
references.citation: J Pathol. 1999 Aug;188(4):369-77
references.pmid: 10440746
references.citation: Lung Cancer. 2004 Aug;45(2):137-42
references.pmid: 15246183
references.citation: J Clin Oncol. 1998 Mar;16(3):1207-17
references.pmid: 9508209
references.citation: Curr Drug Discov Technol. 2009 Jun;6(2):91-102
references.pmid: 19519336
references.citation: Nat Rev Cancer. 2007 Jun;7(6):475-85
references.pmid: 17522716
references.citation: J Clin Oncol. 2001 Jan 15;19(2):432-41
references.pmid: 11208836
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1227-34
references.pmid: 19188680
references.citation: N Engl J Med. 2005 Jul 14;353(2):172-87
references.pmid: 16014887
references.citation: Cancer Cell. 2005 Jan;7(1):101-11
references.pmid: 15652753
references.citation: Dev Biol. 2003 Dec 15;264(2):443-55
references.pmid: 14651929
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Drugs R D. 2008;9(4):261-9
references.pmid: 18588357
references.citation: Lung Cancer. 2001 Nov;34(2):233-41
references.pmid: 11679182
references.citation: N Engl J Med. 2004 Jan 22;350(4):379-92
references.pmid: 14736930
references.citation: Nature. 2005 Dec 15;438(7070):967-74
references.pmid: 16355214
references.citation: Br J Cancer. 2002 Jan 21;86(2):244-9
references.pmid: 11870514
references.citation: J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S128-30
references.pmid: 18520295
references.citation: Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii
references.pmid: 15474332
references.citation: Semin Cancer Biol. 2009 Oct;19(5):338-43
references.pmid: 19481151
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Nature. 1995 Jul 6;376(6535):66-70
references.pmid: 7596436
references.citation: Curr Treat Options Oncol. 2007 Feb;8(1):15-27
references.pmid: 17634832
references.citation: Expert Rev Anticancer Ther. 2009 Jul;9(7):999-1007
references.pmid: 19589038